Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth
2024 Revenues of $16.5 billion reflect an increase of 6%, in local…
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Teva Pharmaceuticals
CORAL GABLES, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.…
Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 23, 2024 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL…
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025
December 20, 2024 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL…